Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 235.81M P/E - EPS this Y 18.70% Ern Qtrly Grth -
Income -171.44M Forward P/E -1.58 EPS next Y 5.30% 50D Avg Chg -20.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -29.00%
Dividend N/A Price/Book 0.98 EPS next 5Y - 52W High Chg -63.00%
Recommedations 2.10 Quick Ratio 4.24 Shares Outstanding 52.67M 52W Low Chg 36.00%
Insider Own 1.92% ROA -49.01% Shares Float 20.06M Beta 1.02
Inst Own 109.15% ROE -92.17% Shares Shorted/Prior 9.98M/9.08M Price 5.77
Gross Margin - Profit Margin - Avg. Volume 218,906 Target Price 9.33
Oper. Margin - Earnings Date Nov 11 Volume 81,047 Change -3.19%
About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

ALX Oncology Holdings Inc. News
09/09/24 ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
09/04/24 ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
08/08/24 ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
08/06/24 ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
08/01/24 Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
08/01/24 ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial
07/31/24 ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
07/31/24 ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
07/09/24 IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
07/09/24 Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
07/08/24 Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
07/05/24 Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
07/04/24 Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
07/03/24 Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
07/03/24 Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
07/02/24 Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
07/01/24 Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
07/01/24 PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
06/28/24 Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
06/27/24 Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
ALXO Chatroom

User Image Moneywheel Posted - 3 days ago

$ALXO looking good....for now.

User Image Moneywheel Posted - 3 days ago

$ALXO ready to run? If price action moves above 2,42$ on a closing basis we may open a leg higher towards 3,37$. Holding strong.

User Image Moneywheel Posted - 4 days ago

$ALXO curling. Going higher. Holding strong.

User Image no_more_fake_news Posted - 1 week ago

$ALXO Selling is likely done. No volume. Down from 18 to 2. Off of 1.88. Cash through Q1 2026

User Image Moneywheel Posted - 1 week ago

$ALXO liking it a lot…

User Image ShortSqueezeRILY Posted - 1 week ago

$WOLF $ALXO

User Image RoyMunson69 Posted - 1 week ago

$ALXO lol

User Image fda_tracker Posted - 2 weeks ago

$ALXO Phase 2 trial w/est Sep completion date NCT05167409: https://www.clinicaltrials.gov/study/NCT05167409 Trial Tracker: https://www.fdatracker.com/trial-tracker/

User Image Stock_Titan Posted - 2 weeks ago

$ALXO ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi https://www.stocktitan.net/news/ALXO/alx-oncology-announces-first-patients-dosed-with-evorpacept-and-95yzjhcytwq9.html

User Image Jabed206 Posted - 08/30/24

$ALXO Don't touch until $1.80

User Image trade_the_gaps Posted - 08/28/24

$ALXO small bio stock companies are 90% pump and dump trash, this will touch under $1 by 2025 then follow by a reverse split.

User Image insidemoney Posted - 08/27/24

$ALXO ALX Oncology Holdings 14-Day RSI: 26.4 % from 52-Week Low: +3.9% % from 52-Week High: -86.6% Open Interest: 4,984 % Change: 0% Put/Call Ratio: 0.21 % Change: -0.1%

User Image Moneywheel Posted - 08/26/24

$ALXO liking it a lot.

User Image insidemoney Posted - 08/21/24

Unusual Options Volume (Aug 20) $TERN Terns Pharmaceuticals Volume 5,619 Average 688 (x 8.2) $ALXO Alx Oncology Holdings Volume 5,520 Average 785 (x 7) $KEYS Keysight Techs Volume 5,472 Average 834 (x 6.6) Earnings 20-Aug-2024 AMC

User Image intratio Posted - 08/21/24

https://www.intratio.com/stock-forecast/ALXO Our network has detected the stock price of this company has a clear poor short-term setup and, in the long run, faces severe disadvantages $ALXO

User Image intratio Posted - 4 weeks ago

https://www.intratio.com/stock-forecast/ALXO ALX ONCOLOGY HOLDINGS INC The model foretells this stock s price action has a clear poor short-term setup and will continue to have a very poor trend over the next months $ALXO

User Image insiderbuyingselling Posted - 1 month ago

$ALXO new insider selling: 1365 shares. http://insiderbuyingselling.com/?t=ALXO

User Image AnaChart Posted - 1 month ago

$ALXO https://anachart.com/wp-content/uploads/ana_temp/1723820524_soc-img.jpg

User Image Azhrarn Posted - 1 month ago

$ALXO Holding a 5k position here. 20% underwater at current levels. But still seeing a good chance for a reversal.

User Image james2609 Posted - 1 month ago

$ALXO saw 5 strike call bot and put sold. It is just an option arbitrage and nothing else.

User Image Jabed206 Posted - 1 month ago

$ALXO hardly any sellers below $2.40

User Image Jabed206 Posted - 1 month ago

$ALXO expecting this to go to $3.30 in the next few weeks.

User Image Jabed206 Posted - 1 month ago

$ALXO selling I think is mostly done now

User Image benny2800 Posted - 1 month ago

$ALXO worst stock ever

User Image Jabed206 Posted - 1 month ago

$ALXO https://pmlive.com/pharma_news/alx-oncologys-evorpacept-shows-promise-as-gastric-cancer-combination-treatment/

User Image Jabed206 Posted - 1 month ago

$ALXO accumlated 2000 shares under 2.50

User Image tradertup Posted - 1 month ago

$ALXO Insiders loaded for $8+ .. This will have move upside soon !

User Image dowjam Posted - 1 month ago

$ALXO wtf checkout aug call and put volume at 5 .... massive and only one week to go .... Monday news ???

User Image Stocktiktaker Posted - 1 month ago

$ALXO

User Image epsguid Posted - 1 month ago

$ALXO reported a loss of $0.76, consensus was ($0.77) via @eWhispers #epsbeat http://eps.sh/d/alxo

Analyst Ratings
UBS Buy Aug 16, 24
HC Wainwright & Co. Buy Aug 13, 24
Cantor Fitzgerald Overweight Aug 12, 24
Stifel Hold Aug 9, 24
Stifel Hold Aug 1, 24
HC Wainwright & Co. Buy Aug 1, 24
HC Wainwright & Co. Buy Jun 10, 24
Cantor Fitzgerald Overweight May 29, 24
Cantor Fitzgerald Overweight Apr 12, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Pinto Shelly VP, Finance and CAO VP, Finance and CAO Dec 29 Sell 11.0699 482 5,336 62,097 01/03/23
Randolph Sophia Chief Medical Office.. Chief Medical Officer Dec 29 Sell 11.0704 1,617 17,901 270,253 01/03/23
GARCIA PETER S Chief Financial Offi.. Chief Financial Officer Dec 29 Sell 11.0701 893 9,886 53,723 01/03/23
Pons Jaume President & CEO President & CEO Dec 29 Sell 11.0701 3,232 35,779 539,746 01/03/23
Randolph Sophia Chief Medical Office.. Chief Medical Officer Dec 16 Option 3.6 46,474 167,306 271,870 12/20/22
GARCIA PETER S Chief Financial Offi.. Chief Financial Officer Feb 07 Option 4.45 15,000 66,750 24,483 02/08/22
Pons Jaume President & CEO President & CEO Feb 03 Option 1.45 24,154 35,023 468,978 02/07/22
Randolph Sophia Chief Medical Office.. Chief Medical Officer Dec 15 Option 1.45 23,852 34,585 188,396 12/16/21
Lettmann Jason Director Director Dec 13 Sell 27.91 325,377 9,081,272 285,956 12/15/21
LSV Associates, LLC 10% Owner 10% Owner Dec 13 Sell 27.91 48,390 1,350,565 285,956 12/15/21
Lettmann Jason Director Director Dec 08 Sell 32.17 145,637 4,685,142 291,758 12/10/21
LSV Associates, LLC 10% Owner 10% Owner Dec 08 Sell 32.17 145,637 4,685,142 291,758 12/10/21
Pons Jaume President & CEO President & CEO Oct 19 Sell 54.64 16,700 912,488 444,598 10/20/21
GARCIA PETER S Chief Financial Offi.. Chief Financial Officer Sep 17 Sell 79.63 12,771 1,016,955 9,331 09/17/21
GARCIA PETER S Chief Financial Offi.. Chief Financial Officer Sep 17 Option 4.08 12,771 52,106 20,676 09/17/21
Randolph Sophia Chief Medical Office.. Chief Medical Officer Sep 13 Sell 77.48 7,387 572,345 156,815 09/13/21
Pons Jaume President & CEO President & CEO Aug 20 Sell 63.06 16,700 1,053,102 477,998 08/20/21